Effect of valproic acid on mitochondrial epigenetics

Area of Science:

• Biochemistry
• Epigenetics
• Mitochondrial Biology

Background:

• Valproic acid (valproate) is a histone deacetylase inhibitor used in neuroscience research.
• Previous studies focused on nuclear DNA, leaving mitochondrial DNA (mtDNA) epigenetic effects of valproate unexplored.
• Investigating valproate's impact on mtDNA modifications like 5-methylcytosine (5 mC) and 5-hydroxymethylcytosine (5 hmC) is crucial.

Purpose of the Study:

• To investigate the effects of short-term and prolonged valproate treatment on mtDNA epigenetic modifications.
• To examine the influence of valproate on ten-eleven-translocation (TET) enzyme expression and mitochondrial localization.
• To elucidate the mechanisms underlying valproate-induced changes in mtDNA epigenetics.

Main Methods:

• Treatment of mouse 3T3-L1 cells with valproate for 1 and 3 days.
• Quantification of global mtDNA 5 mC and 5 hmC levels.
• Analysis of TET enzyme mRNA expression and TET1 protein levels in mitochondria.
• Comparison with effects of MS-275, a class I histone deacetylase inhibitor.

Main Results:

• Prolonged valproate treatment significantly decreased mtDNA 5 hmC content, but not 5 mC.
• Valproate treatment reduced Tet1 mRNA expression and mitochondrial TET1 protein levels.
• The effects of valproate on mtDNA 5 hmC were mimicked by the histone deacetylase inhibitor MS-275.

Conclusions:

• Valproate's prolonged administration can decrease mtDNA 5 hmC, likely through epigenetic mechanisms involving TET1.
• Nuclear histone deacetylase inhibition by valproate may indirectly affect mitochondrial epigenetics.
• Understanding these effects is vital for evaluating valproate's therapeutic and adverse outcomes.